- Sunday, March 15, 2026
- India +91 7982732466
- U.S +1 217 953 4020
- Info@Shingetsuresearch.com
Global T-Cell Therapy Market by Modality (Research, and Commercialized), By Therapy (CAR T-Cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes), By Indication (Hematologic Malignancies (Lymphoma, Leukemia, and Myeloma) and Solid Tumors (Melanoma, Brain & Central Nervous System, Liver cancer and others)), and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa)
Global T-Cell Therapy Market Overview:
The global T-cell therapy market is estimated to reach USD 32.6 billion by 2030, growing at a CAGR of 35.1% during the forecast period of 2022-2030. It was valued at USD 4.1 billion in 2022. T-Cell Therapy is a new immunity that uses specially transformed T-cells to more specifically target cancer cell therapy. T-cell therapy uses immune cells extracted from the patient’s blood to recompile them to identify and attack specific proteins found in brain tumors, and then re-import the immune cells into the patient’s body system. Through genetic modification technology, the targeting, killing activity, and durability of effector T cells are higher than those of conventionally applied immune cells. It can overcome the local immunosuppressive microenvironment of the tumor and break the host’s immune tolerance state. However, this technology also has clinical application risks such as cytokine storms, off-target effects, and insertion mutations.Global T-Cell Therapy Market Insights
It is primarily attributed to factors such as the growing incidence of cancer and the increasing number of patients showing response failure to alternative treatments. Additionally, investments by government bodies are comparatively less in throat cancer, and brain tumor segment will accelerate the growth of the global T-cell therapy market in the upcoming periods. Moreover, the upsurge in the number of adults and children developing cancer would lead to the robust growth of the global T-cell therapy market size in the forecast span. At present, T-cell therapy has been approved by the US Food and Drug Administration (FDA) as some refractory non-Hodgkin lymphoma (refractory non-Hodgkin lymphoma), and childhood relapsed acute lymphoblastic leukemia (pediatric relapsed acute lymphoblastic leukemia, ALL) standard of care. With the approval of Kymriah and Yescarta by FAD, various companies started to develop small molecule and protein-based therapies to adoptive T cell therapy. Further, clinical success and accelerated product approvals projected to drive the global T-cell therapy market industry. The growing demand for t-cell therapy in patients with blood cancer or hematologic cancer through acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphomas will promulgate the t-cell therapy market share in the upcoming periods. Hematological tumors are developing steadily. Solid tumors are seeking breakthroughs. Due to the unique properties and target specificities of hematological tumors, T cell therapy has made significant breakthroughs in the treatment of hematological malignant tumors and demonstrated strong strength.Growth Driver
The surge in demand for T-Cell Therapy in cancer treatment
T-cell therapy is one of the best immunotherapies today. Although it has a unique effect on hematological malignancies, the shortcomings of this therapy are also obvious. T-cell therapy is currently targeting hematological tumors and is still helpless to solid tumors, but most tumors are solid tumors. Fortunately, the fourth-generation T-cell therapy has already experimented with solid tumors. T-cell therapy uses genetically modified immune cells to kill tumors. It has become a life-saving medicine for a large number of patients with lymphoma and leukemia to relieve their pain. According to WHO, the second leading cause of death globally is cancer that responsible for an estimated 9.6 million deaths in 2018. The global cancer burden is projected to have risen from 9.6 million deaths in 2018 and 18.1 million new cases.Therapy Segmental Analysis
Based on therapy, the global t-cell therapy market classified into CAR T-Cell Therapy, T Cell Receptor (TCR), and Tumor-Infiltrating Lymphocytes. The CAR T-Cell Therapy segment predicted to gain a major in the t-cell therapy market by 2030. It is owing to the growing demand for efficient cancer treatment models coupled with CAR-T cell therapy that uses genetically modified immune cells to kill tumors and has become a life-saving medicine for a large number of patients with lymphoma and leukemia to relieve their pain. The T Cell Receptor (TCR) segment will drive with a significant rate in the forecast period as it is used to recognize a tumor-specific protein fragment/MHC combination.Modality Segmental Analysis
Based on modality, the global t-cell therapy market bifurcated into Research and Commercialized. The research segment projected to generate maximum revenue in the market by 2030. It is due to most of the products of t-cell therapy that are under the clinical investigation stage along with the large number of research centers considering it as a profitable method of cancer management in the upcoming years. The Commercialized segment will be the fastest-growing segment in the forecast period owing to the rules and regulatory agencies providing license and provide support for the commercialization of t-cell therapy.Indication Segmental Analysis
Based on indication, the global t-cell therapy market classified into Hematologic Malignancies (Lymphoma, Leukemia, and Myeloma) and Solid Tumors (Melanoma, Brain & Central Nervous System, Liver cancer, and others). The Hematologic Malignancies witnessed a higher share in 2021 and estimated to dominate the t-cell therapy market by 2030. It is due to t-cell used for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma. It is used for recognizing and eliminating cancer cells. Solid Tumors will grow with a momentous rate during the forecast period owing to t-cell therapy used in the treatment of including melanoma, breast cancer, and sarcoma.Region Segmental Analysis
Based on geography, the global T-Cell Therapy market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America estimated to occupy the lion’s share in the t-cell therapy by 2030, owing to the presence of a large number of research centers and the rise in the incidence of cancer in the USA. The European market will influence during the forecast periods due to the approval of CAR T-cell Therapy products along with the presence of key players in these regions.Competitor Analysis
Companies such as Novartis AG, Gilead Sciences, bluebird bio, TCR2 Therapeutics Inc., Sorrento Therapeutics, Kite Pharma, Merck KGaA, Pfizer, Amgen, Celgene Corporation and Fate Therapeutics are the key players in the Global T-Cell Therapy Market.Key Stakeholders
- Market research and consulting firms
- Industry associations
- Global T-Cell Therapy manufacturing firm
- Research organizations and consulting companies
- Organizations, associations, and alliances related to T-Cell Therapy
- Regulatory bodies
- Suppliers
- Retailers
- In December 2021, Lonza cooperated with Agilent Technologies, Inc. to incorporate the latter’s analytical technologies with Cocoon Platform.
The objective of the Research
- Market modeling starts with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
- Product analysis involves steps such as examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
- Market Trend and Economic Factors Analysis helps in assessing potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
- Market Segmental Analysis defines in-depth scenario of the target market by the process of grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics
- The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs wants, and cultural characteristics that can be specifically targeted.
Market Modelling
By Modality- Research
- Commercialized
- CAR T-Cell Therapy
- T Cell Receptor (TCR)
- Tumor Infiltrating Lymphocytes
- Hematologic Malignancies
- Lymphoma
- Leukemia
- Myeloma
- Solid Tumors
- Melanoma
- Brain & Central Nervous System
- Liver cancer
- Others
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
More Related Reports:
Passenger Baggage Tracking Mobile Application Market
Global HR Payroll Software Market
Job Evaluation Software Market
Global Video Conferencing Market
Global Cellular Health Screening Market
Report Content
- Research Strategic Development
1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation
- Research Methodology
2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation
- Executive Summary
- Market Insights
4.1. Supply Chain Analysis
4.2. Economic Factor Analysis
4.2.1. Drivers
4.2.2. Trends
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape
4.4. Competitors & Product Analysis
4.5. Regulatory Framework
4.6. Company market share analysis, 2022
4.7. Porter’s Five forces analysis
4.8. Price point analysis
4.9. New Investment Analysis
4.10. PESTEL Analysis
- Global T-cell Market Overview
5.1. Market Size & Forecast,2017-2030
5.1.1. Demand
5.1.1.1. By Value (USD Billion)
5.2. Market Share & Forecast, 2017-2030
5.2.1. By Modality
5.2.1.1. Research
5.2.1.2. Commercialized
5.2.2. By Therapy Type
5.2.2.1. CAR T-Cell Therapy
5.2.2.2. T Cell Receptor (TCR)
5.2.2.3. Tumor-Infiltrating Lymphocytes
5.2.3. By Indication
5.2.3.1. Hematologic Malignancies
5.2.3.1.1. Lymphoma
5.2.3.1.2. Leukemia
5.2.3.1.3. Myeloma
5.2.3.2. Solid Tumors
5.2.3.2.1. Melanoma
5.2.3.2.2. Brain & Central Nervous System
5.2.3.2.3. Liver cancer
5.2.3.2.4. Others
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. Asia-Pacific
5.2.4.4. South America
5.2.4.5. The Middle East & Africa
- North America T-cell Market Overview
6.1. North America T-cell Market Size & Forecast,2017-2030
6.1.1. Demand
6.1.1.1. By Value (USD Billion)
6.2. Market Share & Forecast, 2017-2030
6.2.1. By Modality
6.2.1.1. Research
6.2.1.2. Commercialized
6.2.2. By Therapy Type
6.2.2.1. CAR T-Cell Therapy
6.2.2.2. T Cell Receptor (TCR)
6.2.2.3. Tumor-Infiltrating Lymphocytes
6.2.3. By Indication
6.2.3.1. Hematologic Malignancies
6.2.3.1.1. Lymphoma
6.2.3.1.2. Leukemia
6.2.3.1.3. Myeloma
6.2.3.2. Solid Tumors
6.2.3.2.1. Melanoma
6.2.3.2.2. Brain & Central Nervous System
6.2.3.2.3. Liver cancer
6.2.3.2.4. Others
6.2.4. By Country
6.2.4.1. US
6.2.4.2. Canada
6.2.4.3. Mexico
6.2.5. Company Market Share (Top 3-5)
6.2.6. Economic Impact Study on North America T-cell Market
- Europe T-cell Market Overview
7.1. Europe T-cell Market Size & Forecast,2017-2030
7.1.1. Demand
7.1.1.1. By Value (USD Billion)
7.2. Market Share & Forecast, 2017-2030
7.2.1. By Modality
7.2.1.1. Research
7.2.1.2. Commercialized
7.2.2. By Therapy Type
7.2.2.1. CAR T-Cell Therapy
7.2.2.2. T Cell Receptor (TCR)
7.2.2.3. Tumor-Infiltrating Lymphocytes
7.2.3. By Indication
7.2.3.1. Hematologic Malignancies
7.2.3.1.1. Lymphoma
7.2.3.1.2. Leukemia
7.2.3.1.3. Myeloma
7.2.3.2. Solid Tumors
7.2.3.2.1. Melanoma
7.2.3.2.2. Brain & Central Nervous System
7.2.3.2.3. Liver cancer
7.2.3.2.4. Others
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. UK
7.2.4.3. France
7.2.4.4. Italy
7.2.4.5. Rest of Europe
7.2.5. Company Market Share (Top 3-5)
7.2.6. Economic Impact Study on Europe T-cell Market
- Asia-Pacific T-cell Market Overview
8.1. Asia-Pacific T-cell Market Size & Forecast,2017-2030
8.1.1. Demand
8.1.1.1. By Value (USD Billion)
8.2. Market Share & Forecast, 2017-2030
8.2.1. By Modality
8.2.1.1. Research
8.2.1.2. Commercialized
8.2.2. By Therapy Type
8.2.2.1. CAR T-Cell Therapy
8.2.2.2. T Cell Receptor (TCR)
8.2.2.3. Tumor-Infiltrating Lymphocytes
8.2.3. By Indication
8.2.3.1. Hematologic Malignancies
8.2.3.1.1. Lymphoma
8.2.3.1.2. Leukemia
8.2.3.1.3. Myeloma
8.2.3.2. Solid Tumors
8.2.3.2.1. Melanoma
8.2.3.2.2. Brain & Central Nervous System
8.2.3.2.3. Liver cancer
8.2.3.2.4. Others
8.2.4. By Country
8.2.4.1. India
8.2.4.2. Japan
8.2.4.3. Australia
8.2.4.4. Rest of Asia Pacific
8.2.5. Company Market Share (Top 3-5)
8.2.6. Economic Impact Study on Asia Pacific T-cell Market
- South America T-cell Market Overview
9.1. South America T-cell Market Size & Forecast,2017-2030
9.1.1. Demand
9.1.1.1. By Value (USD Billion)
9.2. Market Share & Forecast, 2017-2030
9.2.1. By Modality
9.2.1.1. Research
9.2.1.2. Commercialized
9.2.2. By Therapy Type
9.2.2.1. CAR T-Cell Therapy
9.2.2.2. T Cell Receptor (TCR)
9.2.2.3. Tumor-Infiltrating Lymphocytes
9.2.3. By Indication
9.2.3.1. Hematologic Malignancies
9.2.3.1.1. Lymphoma
9.2.3.1.2. Leukemia
9.2.3.1.3. Myeloma
9.2.3.2. Solid Tumors
9.2.3.2.1. Melanoma
9.2.3.2.2. Brain & Central Nervous System
9.2.3.2.3. Liver cancer
9.2.3.2.4. Others
9.2.4. By Country
9.2.4.1. Brazil
9.2.4.2. Argentina
9.2.4.3. Rest of South America
9.2.5. Company Market Share (Top 3-5)
9.2.6. Economic Impact Study on South America T-cell Market
- The Middle East & Africa T-cell Market Overview
10.1. The Middle East & Africa T-cell Market Size & Forecast,2017-2030
10.1.1. Demand
10.1.1.1. By Value (USD Billion)
10.2. Market Share & Forecast, 2017-2030
10.2.1. By Modality
10.2.1.1. Research
10.2.1.2. Commercialized
10.2.2. By Therapy Type
10.2.2.1. CAR T-Cell Therapy
10.2.2.2. T Cell Receptor (TCR)
10.2.2.3. Tumor-Infiltrating Lymphocytes
10.2.3. By Indication
10.2.3.1. Hematologic Malignancies
10.2.3.1.1. Lymphoma
10.2.3.1.2. Leukemia
10.2.3.1.3. Myeloma
10.2.3.2. Solid Tumors
10.2.3.2.1. Melanoma
10.2.3.2.2. Brain & Central Nervous System
10.2.3.2.3. Liver cancer
10.2.3.2.4. Others
10.2.4. By Country
10.2.4.1. Saudi Arabia
10.2.4.2. UAE
10.2.4.3. South Africa
10.2.4.4. Rest of the Middle East & Africa
10.2.5. Company Market Share (Top 3-5)
10.2.6. Economic Impact Study on Middle East & Africa T-cell Market
- Competitor Analysis
11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1. Novartis AG
11.7.2. Gilead Sciences
11.7.3. bluebird bio
11.7.4. TCR2 Therapeutics Inc.
11.7.5. Sorrento Therapeutics
11.7.6. Kite Pharma
11.7.7. Merck KGaA
11.7.8. Pfizer
11.7.9. Amgen
11.7.10. Celgene Corporation
11.7.11. Fate Therapeutics
11.7.12. Other Prominent Players
Frequently Asked Questions (FAQ)
The global T-cell therapy market is estimated to reach USD 32.6 billion by 2030, growing at a CAGR of 35.1% during the forecast period of 2022-2030. It was valued at USD 4.1 billion in 2022.
The upsurge in the number of adults and children developing cancer would lead to the robust growth of the global T-cell therapy market.
Companies such as Novartis AG, Gilead Sciences, bluebird bio, TCR2 Therapeutics Inc., Sorrento Therapeutics, Kite Pharma, Merck KGaA, Pfizer, Amgen, Celgene Corporation and Fate Therapeutics are the key players in the Global T-Cell Therapy Market.
North America is estimated to occupy the largest share in the t-cell therapy.
